EV/EBITDA Ratio: 45.64x

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

Is the EV/EBITDA ratio high or low?

The EV/EBITDA ratio of 45.64x is in line with its estimated 2-year average of 44.91x, near the low end of its estimated 2-year range (25.43x–164.20x).

As of 2026-10-06T16:17:28.247Z. 0.13% above its estimated 12-month average of 45.58x.

KRYS EV/EBITDA Ratio Metrics

EV/EBITDA vs. estimated history

At 45.6, EV/EBITDA is near its estimated 2-year median — higher than 45% of readings in its estimated 2-year history.

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/EBITDA Ratio FAQ

What is the EV/EBITDA ratio for Krystal Biotech, Inc. (KRYS)?

The EV/EBITDA ratio for KRYS stock is 45.64x.

Is Krystal Biotech, Inc.'s EV/EBITDA ratio high or low?

The EV/EBITDA ratio of 45.64x is in line with its estimated 2-year average of 44.91x, near the low end of its estimated 2-year range (25.43x–164.20x).

What is the estimated TTM average EV/EBITDA ratio for Krystal Biotech, Inc. (KRYS)?

The estimated TTM average EV/EBITDA ratio for KRYS stock is 45.58x.

Showing the most recent 260 of 479 data points. The chart above shows the full history.

Related Metrics